Astellas doses first patient in phase 3 VMS trial of fezolinetant

Japanese pharma company Astellas Pharma has dosed the first patient in the SKYLIGHT 1 phase 3 trial for fezolinetant, an investigational oral, non-hormonal compound for the treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause. Vasomotor symptoms are hot flashes and night sweats which occur in nearly 57% on women, aged 40-64 years as per […]

The post Astellas doses first patient in phase 3 VMS trial of fezolinetant appeared first on PharmaNewsDaily.com.

Japanese pharma company Astellas Pharma has dosed the first patient in the SKYLIGHT 1 phase 3 trial for fezolinetant, an investigational oral, non-hormonal compound for the treatment of moderate-to-severe vasomotor symptoms (VMS) associated with .

Vasomotor symptoms are hot flashes and night sweats which occur in nearly 57% on women, aged 40-64 years as per Makara-Studzińśka MT, Kryś-Noszczyk KM, Jakiel G. Epidemiology of the symptoms of menopause – an intercontinental review.

Fezolinetant has been designed to be a selective neurokinin-3 (NK3) receptor antagonist. The non-hormonal compound functions by preventing neurokinin B (NKB) signaling and normalizing KNDy (kisspeptin/NKB/dynorphin) neuron activity, which regulates the temperature control center and lowers the frequency and severity of hot flashes.

See also  Aurobindo Pharma to acquire Sandoz US dermatology and oral solids divisions for $1bn

SKYLIGHT 1 marks the first trial of the BRIGHT SKY clinical development program that will assess the efficacy and safety of 30 and 45 mg once-daily (QD) fezolinetant in reducing the frequency and severity of vasomotor symptoms.

Astellas doses first patient in phase 3 VMS trial of fezolinetant

Astellas doses first patient in phase 3 VMS trial of fezolinetant. Photo courtesy of Stuart Miles/Freedigitalphotos.net.

Salim Mujais – Senior Vice President and Therapeutic Area Head, Medical Specialties of Astellas Pharma said: “There are currently limited non-hormonal options for managing vasomotor symptoms, which can be quite disruptive and often interfere with daily life.

See also  FDC Limited gets GMP certificate for ophthalmic facility from UK MHRA

“With the initiation of our Phase 3 fezolinetant program, we move further towards our goal of providing women with a non-hormonal treatment for moderate-to-severe hot flashes.”

Related posts

See also  Eusa Pharma completes $115m acquisition of Sylvant for iMCD treatment

The post Astellas doses first patient in phase 3 VMS trial of fezolinetant appeared first on PharmaNewsDaily.com.


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

Related Posts

CATEGORIES
Share This